Real‐life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients-Reference-Cited by-同舟云学术

Real‐life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients

Published:2022-11-28 Issue:6 Volume:10 Page:
ISSN:2052-1707
Container-title:Pharmacology Research & Perspectives
language:en
Short-container-title:Pharmacology Res & Perspec

Author:

Kos Renate¹^ORCID,Neerincx Anne H.¹,Fenn Dominic W.¹²,Brinkman Paul¹,Lub Rianne¹,Vonk Steffie E. M.³,Roukema Jolt⁴,Reijers Monique H.⁵,Terheggen‐Lagro Suzanne W. J.⁶,Altenburg Josje¹,Majoor Christof J.¹,Bos Lieuwe D.¹⁷,Haarman Eric G.⁶,Maitland‐van der Zee Anke H.¹⁶,

Affiliation:

1. Department of Respiratory Medicine Amsterdam University Medical Centres – loc. AMC Amsterdam The Netherlands

2. Laboratory of Experimental Intensive Care and Anaesthesiology Amsterdam University Medical Centres – loc. AMC Amsterdam The Netherlands

3. Department of Hospital Pharmacy Amsterdam University Medical Centres – loc. AMC Amsterdam The Netherlands

4. Department of Paediatric Pulmonology, Amalia Children's Hospital Radboud University Medical Center Nijmegen The Netherlands

5. Department of Pulmonology Radboud University Medical Center Nijmegen The Netherlands

6. Department Paediatric Respiratory Medicine and Allergy, Emma Children's Hospital Amsterdam University Medical Centres Amsterdam The Netherlands

7. Department of Intensive Care Amsterdam University Medical Centres – loc. AMC Amsterdam The Netherlands

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/prp2.1015

Reference18 articles.

1. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis

2. Cystic Fibrosis Foundation Patient Registry 2019 Annual Data Report Bethesda Maryland Maryland.2020.https://www.cff.org/Research/Researcher‐Resources/Patient‐Registry/2019‐Patient‐Registry‐Annual‐Data‐Report.pdf

3. Nederlandse CF Registratie 2020. Baarn.2020.

4. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

5. Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis;Frontiers in Pharmacology;2023-12-14

2. Long-term clinical outcomes of elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis and advanced pulmonary disease;Respiratory Medicine;2023-11

3. A longitudinal analysis of respiratory symptoms in people with cystic fibrosis with advanced lung disease on and off ETI;Journal of Cystic Fibrosis;2023-11

4. Use of CFTR modulators in special populations, part 2: Severe lung disease;Pediatric Pulmonology;2023-09-20

5. Cystic fibrosis year in review 2022;Pediatric Pulmonology;2023-08-18